PLSEPLSEHealthcare · Medical Instruments & Supplies

PLSE Stock Forecast: Pulse Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$46
+2.61% on the day

The 6 Wall Street analysts covering Pulse Biosciences, Inc. hold a median 12-month price target of $68 — +48.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$3.3B
Ticker Nerd rank
54/ 100
Median analyst target
$68
Analysts covering
6
Revenue$434K
Operating income−$25.3M
Net income−$24.7M
Free cash flow−$18.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.7%
1M
−10.4%
YTD
+231.9%
1Y
+260.0%
From 52W high
−21.7%
From 52W low
+260.0%
$13
$58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pulse Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
54/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Growth
77
Accruals
66
Revisions
60
Issuance
49
Volatility
35
Value
34
Quality
19

Momentum (97): The shares have been drifting up relative to others.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PLSE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLSE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26PLSEHigh $74Median $68Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$60
Low
$68
Median
$74
High

The green dot is the last close — the median target sits +48.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Canaccord GenuityMaintainsBuy$58 → $74
6 Nov 2026NeedhamMaintainsBuy$58 → $64
13 Oct 2026OppenheimerMaintainsOutperform$35 → $60
6 Oct 2026Canaccord GenuityMaintainsBuy$43 → $58
23 Sept 2026BTIGInitiatesBuy$70
9 Sept 2026Freedom Capital MarketsInitiatesBuy$73
17 Aug 2026NeedhamInitiatesBuy$58
10 Aug 2026Canaccord GenuityMaintainsBuy$32 → $43
4 June 2026Canaccord GenuityInitiatesBuy$32
7 July 2025OppenheimerInitiatesOutperform—
21 Sept 2022Maxim GroupDowngradeHold—
13 May 2022HC Wainwright & Co.DowngradeNeutral—
1 Apr 2022HC Wainwright & Co.MaintainsBuy—
1 Apr 2022Stephens & Co.MaintainsOverweight—
10 Feb 2022HC Wainwright & Co.MaintainsBuy—
16 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 July 2021Stephens & Co.InitiatesOverweight—
11 Mar 2021Maxim GroupInitiatesBuy—
26 Jan 2021HC Wainwright & Co.MaintainsBuy—
12 May 2020H.C. WainwrightUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLSE.

Market Radar

This page is one stock. Monday covers all of them.

PLSE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PLSE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pulse Biosciences, Inc. returned +260.0% against +6.9% for the S&P 500, dividends included.

PLSE vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26PLSES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLSE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2259.6×

Cheaper than 1% of US stocks

Price / book
18.3×

Cheaper than 4% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
359.3%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
37.1%

Higher than 45% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−60.6%

Higher than 19% of US stocks

Return on assets
−35.3%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulse Biosciences, Inc. has a market value of $3.3B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $1.2M.

  • Net income over the same four quarters: −$80.1M, a −6755.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.18.

  • Free cash flow in the twelve months to 30 June 2026: −$61.4M.

  • Shares outstanding: 70.8M.

  • Pulse Biosciences, Inc. employs 116 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PLSE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
PLSEPulse Biosciences, Inc.$3.3B54
NVSTEnvista Holdings Corp.$3.7B96
WRBYWarby Parker, Inc.$2.9B28
ATRCAtriCure, Inc.$2.8B94
ICUIICU Medical, Inc.$4.3B95
STVNStevanato Group SpA$4.3B59
MMEDMiniMed Group, Inc.$4.5B1

Take a look at PLSE’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulse Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PLSE

What is the PLSE stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Pulse Biosciences, Inc. have a median 12-month price target of $68, with estimates ranging from $60 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLSE stock a buy right now?

Of the 6 analysts covering Pulse Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulse Biosciences, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLSE?

As at 21 Nov 2026, Pulse Biosciences, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will PLSE stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +48.1% from the last close, and Ticker Nerd's factor model ranks Pulse Biosciences, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLSE stock forecast for 2030?

No analyst covering Pulse Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $74 over the next 12 months.

How has PLSE stock performed over the past year?

Pulse Biosciences, Inc. returned +260.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulse Biosciences, Inc. do?

Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows.

Company

About Pulse Biosciences, Inc.

Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows. The company serves healthcare providers across dermatology, surgical soft-tissue care, and cardiac electrophysiology, with applications centered on minimally invasive treatment approaches. Pulse Biosciences Inc positions itself within the medical device market through its proprietary energy-based platform, which is designed for clinical use in areas where precise cellular targeting is important.

CEO Mr. Paul Arthur LaViolette M.B.A. · 116 employees · United States · https://www.pulsebiosciences.com